Protagenic Therapeutics, Inc.\new Proceeds from Sale and Maturity of Marketable Securities
Protagenic Therapeutics, Inc.\new (PTIX) reported Proceeds from Sale and Maturity of Marketable Securities of $3.10 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2025-05-13
- Protagenic Therapeutics, Inc.\new proceeds from sale and maturity of marketable securities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from sale and maturity of marketable securities for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from sale and maturity of marketable securities for the quarter ending 2024-06-30 was $1.60M, a 0.75% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from sale and maturity of marketable securities for the quarter ending 2024-03-31 was $1.50M, a 409.05% increase year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from sale and maturity of marketable securities for fiscal 2024 was $3.10M, a 59.69% decline from fiscal 2023.
- Protagenic Therapeutics, Inc.\new proceeds from sale and maturity of marketable securities for fiscal 2023 was $7.69M, a 370.91% increase from fiscal 2022.
- Protagenic Therapeutics, Inc.\new proceeds from sale and maturity of marketable securities for fiscal 2022 was $1.63M, a 236.03% increase from fiscal 2021.
- Protagenic Therapeutics, Inc.\new proceeds from sale and maturity of marketable securities for fiscal 2021 was $485.95K.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $1.60M derived: sum of 3 quarters · filed 2025-03-31 | $3.10M 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | $1.60M derived: sum of 2 quarters · filed 2024-11-14 | $3.10M 10-Q · filed 2024-11-14 | $8.22M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-06-30 | $1.60M 10-Q · filed 2024-08-14 | $3.10M 10-Q · filed 2024-08-14 | $8.22M derived: sum of 3 quarters · filed 2025-05-13 | $8.88M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-03-31 | $1.50M 10-Q · filed 2025-05-13 | $6.62M derived: sum of 2 quarters · filed 2025-05-13 | $7.28M derived: sum of 3 quarters · filed 2025-05-13 | $8.89M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $5.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $5.78M derived: sum of 2 quarters · filed 2025-03-31 | $7.39M derived: sum of 3 quarters · filed 2025-03-31 | $7.69M 10-K · filed 2025-03-31 |
| 2023-09-30 | $659.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.27M derived: sum of 2 quarters · filed 2024-11-14 | $2.57M 10-Q · filed 2024-11-14 | $2.66M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.91M 10-Q · filed 2024-08-14 | $2.00M derived: sum of 3 quarters · filed 2024-08-14 | $2.46M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $294.67K 10-Q · filed 2024-05-15 | $389.00K derived: sum of 2 quarters · filed 2024-05-15 | $849.89K derived: sum of 3 quarters · filed 2024-05-15 | $1.56M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $94.33K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-14 | $555.22K derived: sum of 2 quarters · filed 2024-05-14 | $1.26M derived: sum of 3 quarters · filed 2024-05-14 | $1.63M 10-K/A · filed 2024-05-14 |
| 2022-09-30 | $460.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.17M derived: sum of 2 quarters · filed 2023-11-14 | $1.54M 10-Q · filed 2023-11-14 | $2.02M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $706.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.08M 10-Q · filed 2023-08-14 | $1.56M derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $370.76K 10-Q · filed 2023-05-15 | $856.71K derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $485.95K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-07 | $485.95K 10-K · filed 2022-04-07 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |